Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: Implications for clinical trial design and interpretation Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • The risk-group distribution for metastatic RCC patients in clinical trials shifted from 1975 to 2007. These shifts have direct implications for data analysis, interpretation of metastatic RCC trends, and drug development.

publication date

  • January 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.24713

PubMed ID

  • 19921736

Additional Document Info

start page

  • 347

end page

  • 54

volume

  • 116

number

  • 2